164 related articles for article (PubMed ID: 11791759)
1. Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity.
Cozzi F; Marson P; Rosada M; De Silvestro G; Bullo A; Punzi L; Todesco S
Transfus Apher Sci; 2001 Aug; 25(1):25-31. PubMed ID: 11791759
[TBL] [Abstract][Full Text] [Related]
2. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW
Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328
[TBL] [Abstract][Full Text] [Related]
3. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
4. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS
J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis.
Majewski S; Wojas-Pelc A; Malejczyk M; Szymanska E; Jablonska S
Acta Derm Venereol; 1999 May; 79(3):207-10. PubMed ID: 10384918
[TBL] [Abstract][Full Text] [Related]
6. Bioactivity of prolactin in systemic sclerosis.
La Montagna G; Meli R; Criscuolo T; D'Angelo S; Valentini G
Clin Exp Rheumatol; 2004; 22(2):145-50. PubMed ID: 15083880
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis.
Scheja A; Akesson A; Hørslev-Petersen K
Scand J Rheumatol; 1992; 21(1):5-9. PubMed ID: 1570489
[TBL] [Abstract][Full Text] [Related]
8. Soluble serum interleukin 2 receptors in patients with systemic sclerosis.
Steen VD; Engel EE; Charley MR; Medsger TA
J Rheumatol; 1996 Apr; 23(4):646-9. PubMed ID: 8730120
[TBL] [Abstract][Full Text] [Related]
9. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up--investigations in subclasses and during therapy.
Heickendorff L; Parvez A; Bjerring P; Halkier-Sørensen L; Zachariae H
Acta Derm Venereol; 1991; 71(3):185-8. PubMed ID: 1678217
[TBL] [Abstract][Full Text] [Related]
10. Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease.
La Montagna G; D'Angelo S; Valentini G
J Rheumatol; 2003 Oct; 30(10):2147-51. PubMed ID: 14528508
[TBL] [Abstract][Full Text] [Related]
11. Immunologic parameters in systemic sclerosis.
Bruns M; Herrmann K; Haustein UF
Int J Dermatol; 1994 Jan; 33(1):25-32. PubMed ID: 8112935
[TBL] [Abstract][Full Text] [Related]
12. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease.
Scheja A; Hellmer G; Wollheim FA; Akesson A
Br J Rheumatol; 1993 Jan; 32(1):59-62. PubMed ID: 8422562
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis.
Nagy Z; Czirják L
Clin Exp Rheumatol; 2005; 23(2):165-72. PubMed ID: 15895885
[TBL] [Abstract][Full Text] [Related]
14. Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma.
Zachariae H; Halkier-Sørensen L; Heickendorff L
Acta Derm Venereol; 1989; 69(1):66-70. PubMed ID: 2563612
[TBL] [Abstract][Full Text] [Related]
15. [Effect of Wenyang Huazhuo Tongluo Recipe on Peripheral Blood Thl7/Treg Cell Balance in Systemic Sclerosis Patients].
Bian H; Yuan M; Gao Zhong-ming ; Bi XD; Han L; Hu JL; Mao BY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Aug; 35(8):975-80. PubMed ID: 26485914
[TBL] [Abstract][Full Text] [Related]
16. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis.
Heickendorff L; Zachariae H; Bjerring P; Halkier-Sørensen L; Søndergaard K
J Am Acad Dermatol; 1995 Apr; 32(4):584-8. PubMed ID: 7896946
[TBL] [Abstract][Full Text] [Related]
17. Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations.
Degiannis D; Seibold JR; Czarnecki M; Raskova J; Raska K
Arthritis Rheum; 1990 Mar; 33(3):375-80. PubMed ID: 2317223
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis.
Kiener H; Graninger W; Machold K; Aringer M; Graninger WB
Clin Exp Rheumatol; 1994; 12(5):483-7. PubMed ID: 7842528
[TBL] [Abstract][Full Text] [Related]
19. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis.
Brkic Z; van Bon L; Cossu M; van Helden-Meeuwsen CG; Vonk MC; Knaapen H; van den Berg W; Dalm VA; Van Daele PL; Severino A; Maria NI; Guillen S; Dik WA; Beretta L; Versnel MA; Radstake T
Ann Rheum Dis; 2016 Aug; 75(8):1567-73. PubMed ID: 26371289
[TBL] [Abstract][Full Text] [Related]
20. Skin scoring in systemic sclerosis: a modification--relations to subtypes and the aminoterminal propeptide of type III procollagen (PIIINP).
Zachariae H; Bjerring P; Halkier-Sørensen L; Heickendorff L; Søndergaard K
Acta Derm Venereol; 1994 Nov; 74(6):444-6. PubMed ID: 7701875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]